The Cannabis Use Disorder Market encompasses a range of pharmacological and behavioral therapies designed to treat individuals exhibiting problematic cannabis consumption. Products include small‐molecule antagonists, cognitive‐behavioral therapy programs, and digital health platforms that deliver personalized treatment regimens. Advantages of these offerings include improved patient compliance, reduced relapse rates, and enhanced quality of life for those struggling with withdrawal symptoms and comorbid mental health conditions.

As jurisdictions worldwide legalize recreational and medical cannabis, the incidence of Cannabis Use Disorder Market has surged, creating urgent need for effective interventions. Moreover, healthcare providers are calling for standardized treatment protocols that combine medication with psychosocial support. Market research indicates increasing investments in R&D, driven by strong market trends toward integrated care models and data‐driven outcome tracking. With patent filings on novel cannabinoid receptor modulators and expanding clinical trials, the industry outlook remains robust.

The cannabis use disorder market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.

Key Takeaways

Key players operating in the Cannabis Use Disorder Market are:

-Aelis Farma

-Indivior

-Pfizer

-Corbus Pharmaceuticals

-Zynerba Pharmaceuticals

These market companies lead with innovative pipelines targeting the endocannabinoid system. Aelis Farma is advancing selective CB1 receptor modulators, while Indivior focuses on sublingual formulations proven to ease withdrawal. Pfizer leverages its global R&D infrastructure to repurpose existing neuromodulators, and Corbus Pharmaceuticals is exploring novel anti‐inflammatory approaches that address cannabis‐induced neuroinflammation. Zynerba Pharmaceuticals specializes in transdermal delivery systems, ensuring consistent plasma levels and improved patient adherence. Together, these key players shape market dynamics through strategic collaborations and licensing deals that expand their collective market share and solidify their leadership in cannabis use disorder treatment.

Rising public awareness of mental health and addiction has driven growing demand for specialized cannabis use disorder therapies. As more primary care physicians incorporate screening for substance use, referrals to dedicated clinics and telemedicine services have surged. Market opportunities abound in digital therapeutics, which offer remote monitoring and behavioral coaching at scale. Insurance coverage and government grants are increasingly allocating funds for addiction medicine, creating new revenue streams for device manufacturers and software developers. The expanding patient pool—especially adolescents and young adults—fuels demand for noninvasive interventions, boosting market growth and fostering the development of combination therapy protocols that address both physiological dependence and psychosocial triggers.

‣ Get More Insights On: Cannabis Use Disorder Market

‣ Get this Report in Japanese Language: 大麻使用障害市場

‣ Get this Report in Korean Language: 대마사용장애시장